In mouse xenograft models, rosiglitazone, an activator of PPARγ, demonstrated anti-tumor effects as an early intervention, but not as a treatment, with tumor formation repressing PPARγ and rendering stromal cells insensitive to ligand. The gene discussed is PPARG; the disease is neoplasm.